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Abstract
The study of survival outliers of glioblastoma can provide important clues on gliomagenesis as well as on the ways
to alter clinical course of this almost uniformly lethal cancer type. However, there has been little consensus on
genetic and epigenetic signatures of the long-term survival outliers of glioblastoma. Although the two classical
molecular markers of glioblastoma including isocitrate dehydrogenase 1 or 2 (IDH1/2) mutation and O6-
methylguanine DNA methyltransferase (MGMT) promoter methylation are associated with overall survival rate of
glioblastoma patients, they are not specific to the survival outliers. In this study, we compared the two groups of
survival outliers of glioblastoma with IDH wild-type, consisting of the glioblastoma patients who lived longer than 3
years (n = 17) and the patients who lived less than 1 year (n = 12) in terms of genome-wide DNA methylation
profile. Statistical analyses were performed to identify differentially methylated sites between the two groups.
Functional implication of DNA methylation patterns specific to long-term survivors of glioblastoma were
investigated by comprehensive enrichment analyses with genomic and epigenomic features. We found that the
genome of long-term survivors of glioblastoma is differentially methylated relative to short-term survivor patients
depending on CpG density: hypermethylation near CpG islands (CGIs) and hypomethylation far from CGIs.
Interestingly, these two patterns are associated with distinct oncogenic aspects in gliomagenesis. In the long-term
survival glioblastoma-specific sites distant from CGI, somatic mutations of glioblastoma are enriched with higher
DNA methylation, suggesting that the hypomethylation in long-term survival glioblastoma can contribute to reduce
the rate of somatic mutation. On the other hand, the hypermethylation near CGIs associates with transcriptional
downregulation of genes involved in cancer progression pathways. Using independent cohorts of IDH1/2- wild type
glioblastoma, we also showed that these two patterns of DNA methylation can be used as molecular markers of
long-term survival glioblastoma. Our results provide extended understanding of DNA methylation, especially of
DNA hypomethylation, in cancer genome and reveal clinical importance of DNA methylation pattern as prognostic
markers of glioblastoma.
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Introduction
Despite advances in modern neuro-oncology, glioblast-
oma (GBM) continues to have a poor prognosis. Sur-
vival rates of adult GBM patients in the United States
are quite low with 1-year, 2-year, 3-year, and 5-year
relative survival rates estimated at 39.3, 16.9, 9.9, and
5.5%, respectively [26]. While the majority of GBM
patients live no longer than 2 years, there is a subset of
patients who live longer than 3 years and are classified
as long-term survivors (LTS). This group of patients
remains a puzzle to researchers in the field, as studies
on clinical, radiological, histological, and molecular
characteristics have yet to yield consensus regarding
determinants of durable response to the current treat-
ment [2, 3, 12, 14, 15, 20, 22, 24, 28, 29, 35–37]. For
example, efforts to identify specific gene expression
profiling patterns for LTS-GBM failed to uncover
consistent features [8, 9, 30]. The classic genetic
markers of favorable prognosis of GBM such as O-6-
methylguanine-DNA methyltransferase (MGMT) pro-
moter methylation or isocitrate dehydrogenase (IDH)
mutation do not fully account for long term survivors
of glioblastoma (LTS-GBM) [1, 9, 10, 21, 33, 39]. In
particular, there are few studies for identification of
molecular features associated with glioblastoma inde-
pendent from IDH mutation or the IDH mutation-
related signatures such as DNA methylation pattern
called ‘Glioma CpG Island Hypermethylator Phenotype
(G-CIMP)’ [8]. Although there is a report of concurrent
gain of chromosomes 19 and 20 as a favorable prognos-
tic factor for a subset of LTS-GBM that did not show
G-CIMP, multiple other studies revealed no distinctive
DNA copy number changes in LTS-GBM [9, 10, 30].
These results suggest that there is little chance to
define LTS-GBM with a single genetic or epigenetic
mechanism, emphasizing the importance of integrative
understanding of molecular signatures in LTS-GBM. In
fact, a recent integrated genomic analysis comparing
LTS and short-term survivors (STS) GBM showed that
multiple genetic and epigenetic factors are involved in
divergent molecular features between the two extremes
of the survival spectrum [28].
Although there have been some genome-wide studies
for DNA methylation in survival outliers of brain cancer,
most of them have largely focused on promoter regions
and CpG islands (CGIs) in identifying aberrant methyla-
tion patterns or in classifying GBM due to its readiness
of biological interpretation in terms of transcriptional
regulation [16, 44]. However, the DNA methylation
outside promotor-associated CGIs presents distinctive
signatures in tumors and has significant effects on onco-
genic pathways through multiple mechanisms. For
example, DNA methylation of the CpG sites in gene
body is known to be a major cause of cytosine to
thymine transition mutations, as well as known to
stimulate transcription elongation [11]. Moreover, there
is a genome-wide crosstalk, not limited to genic region,
between DNA methylation and histone modifications
[19, 32]. One good example is that trimethylation of his-
tone H3 lysine 9 (H3K9me3) is required for DNMT3B
dependent de novo DNA methylation [32]. Therefore,
unbiased analysis of DNA methylation across the whole
genome is necessary to perform an integrative analysis
of GBM of exceptional clinical course.
In the present study, we compared genome-wide
DNA methylation profiles of IDH wild-type (IDH WT)
GBM patients who lived longer than 3 years (n = 17,
LTS-GBM) with the patients who lived less than 1 year
(n = 12, STS-GBM). We found the striking differences
in DNA methylation signatures between LTS- and STS-
GBMs and performed integrative analyses for the differ-
ential patterns to understand their functional
implications on epigenetic aspects of GBM. Also, we
evaluated the classification potential of our identified
patterns of DNA methylation with independent cohorts
of mostly IDH WT GBM patients to test their possibil-
ity as prognostic marker.
Materials and methods
Patient samples
Survival data of patients with histologically-confirmed
GBM at Seoul National University Hospital, Korea between
2000 and 2010 were obtained by retrospective review of pa-
tients’ charts, and from National Cancer Registry survival
database of Korea. We identified 34 out of 429 newly diag-
nosed patients who lived longer than 3 years, and 17 pa-
tients were finally selected for discovery cohort of LTS-
GBM group after central histological review. The central
histological review included a complete agreement of histo-
logical diagnosis between two neuropathologists (S.H.P.
and P.B.) on their independent slide review, and no evi-
dence of IDH1 mutation on immuno-histochemical evalu-
ation. For the comparison, 12 GBM patients who lived less
than 1 year in spite of standard care were chosen for the
STS-GBM group. For the validation cohort, 10 GBM sam-
ples were obtained from patients treated at Prince of Wales
Clinical School, Australia between 2004 and 2009 who lived
longer than 3 years. This cohort contained 5 wildtype
IDH1, 1 mutated IDH1, and 4 patients with unknown
IDH1 status. Patients’ clinical characteristics are summa-
rized in the Additional file 1: Table S1. We also collected
IDH WT samples that provide raw data of Illumina’s Infi-
nium Human Methylation450K BeadChips from the cancer
genome atlas (TCGA) dataset: 3 LTS and 39 STS samples.
DNA extraction
DNA was extracted by standard methods for formalin-
fixed paraffin-embedded tumor tissue. The QIAamp
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DNA FFPE Tissue Kit (Qiagen) was used to isolate and
purify DNA from formalin fixed, paraffin embedded
tissue. The protocol suggested by the manufacturer was
used to isolate DNA. The quality and quantity of DNA
was assessed both by Nanodrop and Bioanalyzer tech-
nology. The isolation of DNA from all clinical samples
was performed by the Genetics Core Store of Johns
Hopkins School of Medicine.
Genome-wide DNA methylation measurement
DNA methylation was measured by using Illumina’s
Infinium Human Methylation450K BeadChips (“450K
bead array”) according to the manufacturer’s manual.
DNA bisulfite conversion was carried out using EZ
DNA Methylation Kit (Zymo Research) by following
manufacturer’s manual with modifications for Illumina
Infinium Methylation Assay. Briefly, 400 ng of gen-
omic DNA was first mixed with 5 ul of M-Dilution
Buffer and incubated at 37 °C for 15 min and then
mixed with 100 ul of CT Conversion Reagent prepared
as instructed in the kit’s manual. Mixtures were incu-
bated in a thermocycler with 16 thermal cycles at
95 °C for 30 s and 50C for 1 hour. Bisulfite-converted
DNA samples were loaded onto 96-column plates pro-
vided in the kit for desulphonation and purification. Con-
centration of eluted DNA was measured using Nanodrop-
1000 spectrometer.
Preprocessing of DNA methylation array data: filtering
probes and intra-sample normalization
We filtered the following probes in the 450K bead array: i)
probes whose detection p-values are greater than 0.01 in
more than 5% of samples. According to Illumina, the de-
tection p-value of a probe is calculated by comparing the
intensity of target probes (the sum of methylated bead in-
tensity and unmethylated bead intensity) with the inten-
sities of negative control probes, ii) the probes whose bead
counts are less than 3 in more than 5% of samples, iii)
probes of non-CpG sites, iv) probes with SNP sites, v)
probes whose sequences align to multiple locations in the
reference genome, vi) probes associated with the sex chro-
mosomes. The list of SNP-spanning probes and multiple-
aligned probes were obtained from the R package
“ChAMP” [23]. The 407,351 probes among the total of
485,512 probes in the array were passed in the above fil-
tering. The methylation level of a probe is represented by
the “beta” value that is defined as a ratio of the intensity of
methylation bead to the sum of total intensity of probe
and the offset value of 100.
In the 450K bead array, a probe measures DNA
methylation level with either ‘type I’ assay or ‘type II’
assay. While the probe with type I assay employs two
different bead types for methylation and unmethylation
with the same color channel, the probe with type II
assay uses two different colors with one bead type to
measure methylation and unmethylation status. Since the
two types of probes measure DNA methylation with dif-
ferent chemistries, it is necessary to adjust technical vari-
ation between them. We adopted a beta-mixture quantile
dilation (BMIQ) method proposed by Teschendorff et
al. [40], to perform normalization of beta values
within a sample.
Computational analyses
Differentially methylated sites were identified between
LTS- and STS- GBM groups by using R package, RUV-
inverse for DNA methylation [18]. Briefly, this package
evaluates beta values for a probe with generalized least
squares regression after controlling batch effects based
on negative control probes in the array. The sites were
marked as significant differential methylation if their
corrected p-values for multiple testing by false discovery
rate (FDR) were less than 0.01.
Pearson correlation coefficient was calculated between
DNA methylation level (beta) for a given site and RNA
expression level (log2 transformation of FPKM+ 1) of
the corresponding refSeq mRNA using 32 GBM samples
that are available for both of RNA-seq and 450K bead
array in TCGA. When multiple sites were matched to
a single gene, the maximum value of correlation coef-
ficient was assigned for a gene. We only considered
the sites whose standard deviation of beta values is
greater than 0.1 and mean value of FPKM is greater
than 0 to focus on the sites with enough variation of
DNA methylation and detectable gene expression
across the GBM samples.
The list of somatic mutation in GBM was downloaded
from TCGA for 136 samples that have both of whole
exome sequencing and 450K bead array. In each sample,
a somatic mutation is associated with a probe site if the
mutation is found between 5 K base-pairs upstream and
downstream of a probe site.
Gene ontology (GO) analysis for a given set of sites
on 450K bead array was performed adjusting for the
selection bias of genes inherent from non-uniform
distribution of probes across genome. We took a
weighted resampling approach similar with the previ-
ous report [43]. Specifically, 1000 random sets of as
many genes as the test set were generated with selec-
tion of a gene weighted according to the number of
probes assigned to a gene. Statistical significance of a
GO term was determined by comparing the number
of genes associated with the GO term between the
test set and the randomly-selected gene sets. Signifi-
cant GO terms were selected among the category of
biological process based on FDR threshold of 0.05.
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Probe annotation and open source datasets
The probes on the 450K bead array were annotated
with R package, “IlluminaHumanMethylation450ka
nno.ilmn12.hg19”, except for their assignment to genes
that were determined by the software ANNOVAR [42]
using NCBI reference genes (Refseq). Note that the
probes were grouped into four categories according to
the distance from the closest CGI in the UCSC annota-
tion (Additional file 1: Figure S1): i) “island” if a probe
is inside CGI, ii) “shore” if a probe is within 2000 bases,
iii) “shelf” if a probe is between 2000 and 4000 bases,
iv) “open sea” otherwise. Further categories were made
by distinguishing 5′ and 3′ direction from the closest
CGI denoted by ‘N_’ and ‘S_’ respectively such as ‘N_
shore’ and ‘S_shore’. The probes were also grouped
according to the distance from transcription start sites
(TSS) of the NCBI reference genes: i) “TSS1500” if a
probe is within 200–1500 bases upstream TSS, ii)
“TSS200” if a probe is between 0 and 200 bases
upstream TSS, iii) “1st exon” if a probe is associated
with first exon, iv) “Far” otherwise. If a probe has
multiple categories, the following priority is applied
to determine its single category: 1st Exon>TSS200 >
TSS1500 > Far.
We obtained epigenetic annotation of human genomes
from the ENCODE project [7, 38], specifically the
regions of ChIP enrichment for 12 histone modifications
(H2az, H3K27ac, H3K27me3, H3K36me3, H3K4me1,
H3K4me2, H3K4me3, H3K79me2, H3K9ac, H3K9me1,
H3K9me3, H4K20me1) across 66 cells (Additional file 1:
Figure S2). The results from uniform processing by
ENCODE Analysis Working Group were downloaded
and manually parsed for further analyses. Also, we
obtained H3K9me3 ChIP-seq and 450K bead array data-
sets of H1 from the ENCODE project.
TCGA datasets were downloaded for the level 3 data
of RNA sequencing (RNA-seq), Illumina Infinium
HumanMethylation450 BeadChip and exome sequencing
of available GBM samples: FPKM, beta values and the
compiled list of somatic mutation sites respectively.
For U87MG, a GBM cell line, DNA methylation pro-
filed by 450K bead array was obtained from ENCODE
project. ChIP-seq peak (q-value< 0.05) of H3K27ac was
provided from [13] (GSE36354).
Results
Differential DNA methylation patterns between LTS- and
STS-GBM
The statistical tests comparing the methylation status
of 17 IDH WT LTS-GBM with those of 12 IDH WT
STS-GBM identified 161,794 autosomal sites showing
the significant differences (see material and methods,
FDR < 0.01) in methylation levels (Fig. 1a and
Additional file 2: Table S2). They generally show
moderate differences in methylation level such that
most of the significant sites have mean differences of
beta values less than 0.3 (Additional file 1: Figure S3).
Differentially methylated sites are evenly distributed
throughout the chromosomes (Additional file 1: Figure
S4). Interestingly, the significant sites tend to have
higher methylation level in LTS when they are closer to
CGI or transcription start site (TSS), while lower
methylation was observed in the distant region from is-
land or TSS in LTS compared with STS (Fig. 1b and c).
In order to understand the differential patterns in
greater detail, we investigated the association of the
identified patterns with histone modifications. We
focused on the representative sites of the two pat-
terns of significant sites: the sites inside CGI (‘Is-
land’) that are hypermethylated and the sites that
are hypomethylated in the ‘open sea’ that are far
from CGI. Here, hypermethylation or hypomethyla-
tion indicated higher or lower DNA methylation
levels in LTS relative to STS. The two groups of
representative sites were constructed by selecting
the sites whose mean difference of beta values be-
tween LTS-GBM and STS-GBM was greater than
0.2 in each region, then were correlated with the
genomic regions of histone marks in the ENCODE
consortium dataset (see materials and methods).
The two groups showed distinct enrichment profiles
of histone marks relative to the insignificant methy-
lation sites (Fig. 2a). For example, H3K27ac was
most enriched with hypermethylated sites in island,
however, this was underrepresented in the hypo-
methylated sites in the open sea. On the contrary,
H3K9me3 was mostly enriched in the significant sites in
the open sea while it was depleted in the island. Further-
more, using the publicly- available datasets (ENCODE,
TCGA and Lin et al. 2012) regarding a glioblastoma cell
line, U87MG, we found that the DNA methylation levels
were negatively correlated with the H3K27ac levels at the
hypermethylated sites in island (Fig. 2b, coefficient of
linear regression: − 0.16 with N = 1298, p-value< 10−
15). Although the DNA methylation levels at the
hypomethylated sites did not correlate with H3K9me3
levels in U87MG (Additional file 1: Figure S5), we
confirmed the positive correlation between DNA methyla-
tion levels and H3K9me3 levels at the hypomethylated
sites in a ENCODE H1 cell line (Fig. 2c, coefficient of lin-
ear regression: 0.29 with N = 24,372, p-value< 10− 15).
These results imply that our comparison between LTS-
GBM and STS-GBM identifies differential DNA methyla-
tion signatures with regulatory potential related to specific
histone marks. In fact, both histone marks of H3K27ac
and H3K9me3 are known to be related with DNA methy-
lation [5].
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Functional implications of LTS-GBM-specific DNA
methylation patterns
Enrichment of histone marks of active transcription such as
H3K27ac and H3K9ac in hypermethylated sites inside CGI
suggests their potential in transcriptional regulation. These
sites are also enriched in promoter regions (Additional file
1: Figure S6a). In fact, it is well known that promoter region
is represented by histone marks of H3K9ac and H3K27ac.
As the role of DNA methylation in the promoter region is
known to repress transcription, we tested whether DNA
methylation of these sites is associated with varying gene
expression levels. Specifically, the distribution of correla-
tions between DNA methylation and gene expression
across GBM samples in the TCGA were compared between
these sites and the insignificant genic sites in the CGI. The
distribution of Pearson correlation coefficients was shifted
to the left to the 0 value in the hypermethylated sites while
the non-significant sites in CGI showed bimodal distribu-
tion (Fig. 3a), indicating the enrichment of negative correl-
ation between DNA methylation and gene expression for
the sites showing the hypermethylated sites. We also per-
formed gene ontology (GO) analyses to understand genes
Fig. 1 Differentially methylated sites between LTS-GBM and STS-GBM. a Heatmap of DNA methylation levels measured as beta values: color gradients
from blue to red correspond to beta values from 0 to 1. Hierarchical clustering was performed for both of glioblastoma patients (columns) and the
differentially-methylated sites between LTS-GBM and STS-GBM (rows). Here, hierarchical clustering of the most significant sites (−log10(FDR) < 5: 13,049
sites) with Euclidean distance and complete linkage was performed for convenient visualization. b Distribution of the mean increased level of DNA
methylation in LTS relative to STS (labelled as “LTS-STS” in y-axis) across the sites categorized by their locations from the closest CpG Island (CGI) (see
materials and methods). The group of selected significant sites are denoted by pink while the other sites are described by grey. If the distribution is
shifted to the positive in y-axis (for example, at “Island”), it means that LTS has in general higher DNA methylation compared to STS while the shift to
the negative in y-axis indicates the opposite case (for example, in “OpenSea”). c Same as (b) except that categorization of sites were done by distances
from the nearest transcription start site (TSS) (see materials and methods)
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regulated by hypermethylation in LTS-GBM. Genes associ-
ated with hypermethylated sites in CGI were enriched with
the gene ontology terms related to cancer progression such
as cellular proliferation and cellular attachment (Table 1).
These results collectively imply that hypermethylation
around CGI found in LTS-GBM suppress gene expression
in tumor progression pathways.
The hypomethylated sites in the open sea were slightly
enriched with gene body region (Additional file 1: Figure
S6b). Also, the they showed the enriched positive correla-
tions between DNA methylation and gene expression, be-
ing consistent with the well-known association of DNA
methylation with gene expression in gene body [11] (Add-
itional file 1: Figure S7). However, their effect was not obvi-
ous as much as the hypermethylated sites. In addition, the
hypomethylation-associated genes were not enriched with
GO terms related to cancer (Additional file 1: Table S3).
We concluded that hypomethylation in LTS-GBM is not
involved with gene activity of oncogenic pathway, at least
as much as hypermethylation.
Previous studies suggest that epigenetic modifications of
the genome can affect the mutational rate in the human
genome [17]. We hypothesized that hypomethylation in the
open sea might be related with local mutational rate. Using
the exome sequencing data of GBM in TCGA, we looked
at DNA methylation levels around the somatic mutation in
the open sea (see materials and methods). Interestingly, we
found that the distributions of DNA methylation levels
around somatic mutations are different according to the
sites in the open sea (Fig. 3b). In the LTS-GBM specific
sites, somatic mutations were preferentially observed when
they were highly methylated while the other sites in the
Fig. 2 Enrichment of differentially-methylated sites in regulatory histone marks. a Enrichment patterns of differentially-methylated sites with histone marks.
For a given histone mark (x axis), Y axis value describes the differences of enrichment proportion between the significantly- differential methylation sites
and the insignificant sites. The red denotes hypermethylated sites in island while the blue describes hypomethylated sites in open sea. The size of dot
indicates the range of enrichment proportion of the significantly- differential sites. We grouped the proportion to 4 regions for clear visualization (4 dot
sizes): 0~0.25, 0.25~0.5, 0.5~0.75, 0.75~1. b The relation between the ChIP-seq signal of H3K27ac and the DNA methylation level (beta) for the hyper-
methylated sites in U87MG cell line. Each dot denotes the site. c The same plot as (b) for the hyper-methylated sites in H1 cell line
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open sea showed little bias of DNA methylation. We also
looked into the relative location of the sample with somatic
mutation in the distribution of DNA methylation levels
(136 samples) by calculating Z-score of DNA methylation
level. The hypo-methylated sites tend to have higher DNA
methylation levels in the sample with somatic mutation
relative to the mean DNA methylation levels across the 136
samples that were interrogated here (Additional file 1: Fig-
ure S8). This tendency is weaker in the insignificant sites
(Kolmogorov-Smirnov test, number of hypo-methylated
sites:1802, number of insignificant sites: 5032, p-value <
2.2e-16). These results imply that the hypomethylation in
LTS-GBM occurs at the sites potentially contributing to
lower somatic mutation rates.
Validation of differential methylation in an independent
LTS-GBM cohort
Finally, we asked if our identification of hypermethyla-
tion in CGIs and hypomethylation in open sea is
reproducible in independent cohorts of LTS-GBM.
Hierarchical clustering was performed for two independ-
ent test sets of IDH WT GBM samples (TCGA and
‘Australian’, see materials and methods) using DNA
methylation level at the identified hyper or hypomethy-
lated sites (Fig. 4a). First, all of 9 Australian LTS samples
show similar pattern of hyper and hypomethylation.
Second, 38 out of 39 STS in the TCGA replicated our
pattern while all 3 LTS-GBM samples were not
accounted for by our pattern.
We also attempted to assign scores to each test
sample in terms of hypermethylation and hypomethy-
lation in order to predict LTS-GBM. The simple
arithmetic average of beta values in each pattern is
assigned to a sample. We predicted a sample as LTS-
GBM when its mean beta values for both of hyper-
methylation and hypomethylation are greater than 0.2,
otherwise it was called as STS-GBM. As a result, 9
out of 12 LTS-GBM were predicted correctly
a b
Fig. 3 Functional implication of hyper- and hypo-methylated sites in LTS-GBM. a Distribution of Pearson correlation coefficients between DNA
methylation level (beta) and gene expression measured by RNA-seq (FPKM) across 32 GBM samples in TCGA. The red describes the genes
(number of genes: 366) corresponding to the selected hyper-methylated sites in this study while the gray shows the genes (number of genes:
4413) matched to insignificant sites associated with the island. b DNA methylation level around somatic mutations found in 136 TCGA GBM
samples by whole exome sequencing. The hypo-methylated sites in LTS-GBM (N = 1802) were compared with the insignificant sites in open
sea (N = 5032)
Table 1 Gene Ontology (GO) results of the hyper-methylated sites




GO:0008283 The multiplication or reproduction of cells, resulting in the expansion of a cell population. 50 / 263 0, 0
GO:0016338 The attachment of one cell to another cell via adhesion molecules that do not require the
presence of calcium for the interaction.
6 / 13 0, 0
GO:0071364 Any process that results in a change in state or activity of a cell (in terms of movement,
secretion, enzyme production, gene expression, etc.) as a result of an epidermal growth
factor stimulus.
12 / 33 0.004, 0.019
ID: GO ID, Description: GO Term description, Number of genes: “total” is the number of genes that are mapped in the 450 K bead array in the GO term,
“intersection” means the number of genes that have associations with the selected hyper-methylated sites among the total, Significance: “p-value” was obtained
from permutation test, “FDR” is False Discovery Rate (see materials and methods)
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(sensitivity: 75%) and 38 out of 39 STS samples are
correctly recalled (specificity: 97%) (Fig. 4b).
Discussion
Epigenetic aberrations are increasingly regarded as a
gateway to neoplastic transformation in gliomas [16]. In
particular, a recent study showed that DNA methylation
was the strongest predictor of prolonged survival in
GBM compared to any of clinical variables, RNA expres-
sions for mRNA/miRNA, and the available genomic data
including germline/somatic point mutation and copy
number variation [14]. They found the importance of
DNA methylation based on the statistical analyses for
clinical data and multimodal molecular profiles of 44
patients (7.4%) who lived longer than 3 years among 591
GBM patients from TCGA dataset. However, the effect
of DNA methylation is often confounded with genetic
perturbation. For example, although G-CIMP signatures
were found to be a favorable prognostic marker of GBM
[4, 25], the majority of them overlap with IDH mutation
[27, 41]. Therefore, it is important to evaluate the effect
of DNA methylation in LTS-GBM after controlling gen-
etic background such as IDH mutation. There have been
several studies identifying DNA methylation signatures
specific for IDH WT LTS-GBMs. Mock et al. compared
global DNA methylation profiling using Methyl-CpG-
Immunoprecipitation in 14 LTS and 15 STS-GBM
patient samples with IDH1 wild-type, and found that
hypermethylation of multiple CpGs mapping to the
promoter region of LOC283731 correlated with im-
proved patient outcome [22]. Zhang et al. analyzed
methylation profiles of 13 LTS and 20 STS-GBM
patients using Illumina Infinium Human Methylation 27
K Bead-Chips [44]. They identified the promoter methy-
lation in ALDH1A3 is a prognostic biomarker in a IDH1
wild-type and unmethylated MGMT promoter GBM
sample. However, these studies only focused on DNA
methylation in promoter regions and did not provide
a b
Fig. 4 Hyper- and hypo-methylation in two independent cohorts (TCGA and ‘Australian’). a Heatmap of DNA methylation levels measured as
beta values: hierarchical clustering was performed for both of samples (columns) and the sites (rows) either hyper- or hypo-methylation identified
in the discovery cohort (“SNU”). The color gradients from blue to red correspond to beta values from 0 to 1. b Summary scores in terms of hyper-
and hypo-methylation for each sample in two test cohorts: Each sample, denoted by a dot is assigned to two simple arithmetic averages (x and y
axes values) of beta values in hyper- and hypo- methylation sites. The dashed line indicates 0.2 as a decision threshold for LTS-GBM
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comprehensive understanding of landscape of DNA
methylation signatures in LTS-GBM.
In the present study, we pursued the genome-wide
understanding of DNA methylation patterns specific to
IDH WT LTS-GBM. We showed that LTS-GBM,
compared with STS-GBM, is characterized by hyperme-
thylation in the CGI and hypomethylation at open sea
throughout the genome. It is well known that methyla-
tion of CGIs at promoter region is linked to silence of
gene expression, and our results were consistent with
this idea and previous findings of hypermethylation in
LTS-GBM. However, hypomethylation of open sea in
LTS-GBM is poorly appreciated so far. It is not compel-
ling to understand this pattern in terms of gene activity
since our GO analysis showed that the genes are not
generally related with cancer. Also, as genome-wide
hypomethylation in cancer is known to be ubiquitous
feature of carcinogenesis [6], the hypomethylation
pattern of LTS-GBM relative to STS-GBM seems to
be enigmatic. However, a previous study showed that
methylated cytosine bases are prone to mutation by
spontaneous deamination to thymine [31]. Addition-
ally, there is evidence linking levels of regional muta-
tion density of cancer cells with the heterochromatin-
associated H3K9me3 that is a sole histone mark
enriched with our hypomethylated sites [34]. Our
analysis of exome-sequencing of GBM showed that
local somatic mutations tend to occur near the LTS-
GBM-specific sites in open sea when these sites have
higher DNA methylation levels. This suggests that
Fig. 5 Genome-wide DNA methylation pattern of glioblastoma. The genomes of long-term survivors in glioblastoma are differentially methylated
relative to short-term survival patients depending on CpG density: hypermethylation near CpG islands (CGIs) and hypomethylation far from CGIs (open
sea). The hypermethylation at CGIs frequently occurs around regions with histone marks of active transcription such as H3K27ac, correlating with
downregulation of gene expression in cancer progression pathways. The hypomethylated region at open sea are enriched with a histone mark of
heterochromatin, H3K9me3. The rate of de novo mutation is high in this region when it is methylated, implying survival advantage of hypomethylation
of the region in glioblastoma. In the figure, we highlighted genic regions such as first exon and gene body to emphasize potential effect of perturbed
DNA methylation in glioblastoma
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significantly lower methylation around the identified
sites in LTS-GBM can reduce the risk of de novo
mutation contributable to oncogenesis possibly in the
absence of proper DNA repair mechanisms in GBM.
However, the mechanism of how the hypomethylation
in the region distant from CGI in LTS-GBM affects
the rates of somatic mutation and contributes to
better survival relative to STS-GBM remains to be
determined by further studies.
We also tested whether the two identified genome-
wide patterns were able to serve as molecular markers of
LTS-GBM by applying the identified sites to the inde-
pendent cohorts of LTS samples. Although we con-
firmed the reasonable performance of the sites with the
simple rule of prediction, the LTS samples from TCGA
cohort did not show the predicted pattern. This might
be due to small sample size (N = 3) or unknown batch
effect. We anticipate a larger cohort as well as better
prediction rules in the future study to validate applicabil-
ity of the identified methylation patterns specific to LTS-
GBM.
Conclusion
Our finding provides a clue on functional implications
of global DNA methylation in survival outliers of glio-
blastoma, which are related to oncogenic pathways
through the two distinct mechanisms of transcriptional
suppression and somatic mutation depending on their
genomic location (Fig. 5). The implication of DNA hypo-
methylation specific to long term survivors of glioblast-
oma call more attention to its dual aspects on both
oncogenic contribution and survival benefits of patients.
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